Related Experiment Video

Updated: Jun 19, 2026

Flow Cytometry Analysis of Immune Cells Within Murine Aortas
15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

T-cell co-stimulators as anti-inflammatory targets for atherosclerotic disease

Xiaosong Wang1

  • 1The Jackson Laboratory, 600 Main Street, Bar Harbor, ME 04609, USA. xw@jax.org

Future Cardiology
|October 7, 2009
PubMed

Insights

New atherosclerosis treatments focus on raising high-density lipoprotein (HDL) and targeting T cells involved in inflammation. Modulating T-cell co-stimulators may offer a novel approach to slow this inflammatory disease progression.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Pharmacology

Background:

  • Current atherosclerosis treatments primarily target low-density lipoprotein (LDL) levels.
  • Emerging therapies investigate raising high-density lipoprotein (HDL) and its protective functions.
  • Atherosclerosis is increasingly recognized as an inflammatory disease involving immune cells like T cells.

Purpose of the Study:

  • To explore novel therapeutic strategies for atherosclerosis beyond LDL reduction.
  • To investigate the role of T cells and inflammation in atherosclerosis.
  • To evaluate the potential of targeting T-cell co-stimulators for atherosclerosis treatment.

Main Methods:

  • Review of current pharmacological therapies for atherosclerosis.
  • Analysis of ongoing clinical trials for HDL-raising drugs.
  • Examination of research on immune cell involvement in atherosclerotic lesions.

Main Results:

  • Pharmacological therapies predominantly focus on lowering LDL cholesterol.
  • Clinical trials are exploring HDL-raising strategies and HDL-mediated functions.
  • T cells are present in atherosclerotic lesions at all stages, indicating a key inflammatory role.

Conclusions:

  • Targeting T-cell co-stimulators presents a potential therapeutic avenue.
  • Modulating T-cell-mediated inflammation may slow atherosclerosis progression.
  • Future research should focus on immune system modulation for atherosclerosis treatment.

More Related Videos

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat04:30

Investigating Aortic Valve Calcification via Isolation and Culture of T Lymphocytes using Feeder Cells from Irradiated Buffy Coat

Published on: February 4, 2021

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
T Cell Activation and Clonal Selection01:22

T Cell Activation and Clonal Selection

T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inflammation01:38

Inflammation

Overview